Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rhenium 188-P2045 in advanced neuroendocrine carcinomas
NCT02030184Phase 2Withdrawn
- Sponsor
- University of Maryland, Baltimore
- Start
- Jun 2017
- Primary completion
- Jun 2019
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of 188Re-P2045 in small cell lung cancer (SCLC), Neuroendocrine Neoplasm (NEN), pulmonary large cell neuroendocrine carcinoma (LCNEC), Pulmonary carcinoid tumor, gastrointestinal carcinoid tumor, sponsored by University of Maryland, Baltimore. Planned start Jun 2017; status: withdrawn.
02
Drugs
188Re-P2045
03
Conditions
small cell lung cancer (SCLC)Neuroendocrine Neoplasm (NEN)pulmonary large cell neuroendocrine carcinoma (LCNEC)Pulmonary carcinoid tumorgastrointestinal carcinoid tumor
Beyond the preview
Go deeper on NCT02030184.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02030184.